Exact Sciences Corp (EXAS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Exact Sciences Corp (EXAS:NASDAQ), powered by AI.

Current Price
$104.91
P/E Ratio
-95.2
Market Cap
19.8B
Sector
Healthcare
What is the Exact Sciences Corp stock price forecast?

Exact Sciences Corp is currently trading at $104.91. View real-time AI analysis on Alpha Lenz.

What is Exact Sciences Corp insider trading activity?

View the latest insider trading data for Exact Sciences Corp on Alpha Lenz.

What is Exact Sciences Corp's P/E ratio?

Exact Sciences Corp's P/E ratio is -95.2.

Exact Sciences Corp

NASDAQ · EXAS
$104.91
Ask about Exact Sciences Corp's future dividend policy...
Alpha Chat Insight

Exact Sciences Corp trades at a P/E of -95.2 (undervalued) with modest ROE of -8.7%. 3Y revenue CAGR of 15.9% highlights clear growth momentum.

Ask for details

Company Overview

Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.

CEOMr. Kevin T. Conroy J.D.
SectorHealthcare
IndustryDiagnostics & Research
Employees6,900

Company Statistics

FY 2025

Profile

$19.80BMarket Cap
$3.25BRevenue
0.00Shares Out
6,900Employees

Margins

69.69%Gross
0.55%EBITDA
-6.13%Operating
-6.28%Pre-Tax
-6.40%Net

Valuation

-95.19P/E
8.24P/B
6.10EV/Sales
1195.28EV/EBITDA
55.48P/FCF

Growth (CAGR)

15.92%Rev 3Yr
16.84%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-3.53%ROA
-8.66%ROE
-2.87%ROIC

Financial Health

$956.00MCash & Cash Equivalents
$2.50BNet Debt
144.09%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Exact Sciences Corp (ticker: EXAS) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 6,900 employees. Market cap is $19.8B.

The current price is $104.91 with a P/E ratio of -95.19x and P/B of 8.24x.

ROE is -8.66% and operating margin is -6.13%. Annual revenue is $3.2B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Exact Sciences Corp (Healthcare) Stock Forecast & Analysis $104.91 | Alpha Lenz